Alimera Sciences’ (ALIM) Hold Rating Reiterated at Maxim Group

Alimera Sciences (NASDAQ:ALIM)‘s stock had its “hold” rating reaffirmed by investment analysts at Maxim Group in a note issued to investors on Tuesday, Benzinga reports.

A number of other research firms have also commented on ALIM. HC Wainwright lowered Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price target for the company. in a research report on Tuesday. StockNews.com downgraded Alimera Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th.

Alimera Sciences Price Performance

Shares of NASDAQ ALIM opened at $5.52 on Tuesday. The firm’s fifty day moving average is $3.40 and its 200 day moving average is $3.66. Alimera Sciences has a 52 week low of $2.60 and a 52 week high of $5.65. The company has a quick ratio of 2.51, a current ratio of 2.62 and a debt-to-equity ratio of 1.71. The company has a market cap of $289.19 million, a price-to-earnings ratio of -3.52 and a beta of 1.14.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). The firm had revenue of $23.01 million during the quarter, compared to analysts’ expectations of $23.72 million. Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. During the same quarter in the previous year, the firm posted ($0.71) EPS. On average, equities research analysts expect that Alimera Sciences will post -0.13 earnings per share for the current year.

Institutional Trading of Alimera Sciences

Several institutional investors and hedge funds have recently bought and sold shares of ALIM. Fifth Lane Capital LP purchased a new position in shares of Alimera Sciences during the 1st quarter worth approximately $83,000. Hillsdale Investment Management Inc. bought a new stake in shares of Alimera Sciences during the first quarter valued at approximately $169,000. Ancora Advisors LLC purchased a new stake in Alimera Sciences in the first quarter worth $915,000. Worth Venture Partners LLC bought a new position in Alimera Sciences in the third quarter worth $1,840,000. Finally, Vanguard Group Inc. lifted its position in Alimera Sciences by 61.1% during the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after buying an additional 396,506 shares during the period. 99.83% of the stock is currently owned by hedge funds and other institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).